Metronidazole-Novofarm To the previous page

Marketing Authorization
№ UA/5519/01/01

Pharmaceutical form

Solution for infusion.
Main physical and chemical properties: clear greenish-yellow solution.

Pharmacotherapeutic group

Antimicrobials for systemic use. Imidazole derivatives.

ATC Code J01X D01.

Therapeutic indications

Treatment and prevention of infections caused by microorganisms sensitive to metronidazole (mainly anaerobic bacteria).
The treatment is effective in the following cases:
– central nervous system infections (including brain abscess, meningitis);
– lung and pleural infections (including necrotizing pneumonia, aspiration pneumonia, lung abscess);
– endocarditis;
– gastrointestinal and abdominal infections, including peritonitis, liver abscess, infections after colon or rectal surgeries, purulent lesions of the abdominal or pelvic cavity;
– gynecological infections (including endometritis after hysterectomy or cesarean section, labor fever, septic abortion);
– ENT and oral infections (including acute necrotizing ulcerative gingivitis);
– bone and joint infections (including osteomyelitis);
– gas gangrene;
– septicemia with thrombophlebitis.
For mixed aerobic and anaerobic infections, appropriate antibiotics for the treatment of aerobic infections should be additionally used.
Prophylactic use is always indicated before surgeries with a high risk of anaerobic infections (before gynecological and intra-abdominal surgeries). When using metronidazole, national and international recommendations for the appropriate use of antimicrobials should be considered.


100 mL or 200 mL in glass bottles.

Sales market


Download the instruction